U01 NS045719/NS/NINDS NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2005	1
2008	1
2010	3
2011	1
2012	6
2013	4
2014	2
2015	2
2016	1
2017	2
2019	1
2021	4
2022	2
2023	2
2024	1

1

Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.

Salter A, Lancia S, Kowalec K, Fitzgerald KC, Marrie RA. Salter A, et al. Neurology. 2024 Mar 12;102(5):e209135. doi: 10.1212/WNL.0000000000209135. Epub 2024 Feb 13. Neurology. 2024. PMID: 38350062 Free PMC article.

2

Risk evaluation and monitoring in multiple sclerosis therapeutics.

Clanet MC, Wolinsky JS, Ashton RJ, Hartung HP, Reingold SC. Clanet MC, et al. Mult Scler. 2014 Sep;20(10):1306-11. doi: 10.1177/1352458513513207. Epub 2013 Nov 30. Mult Scler. 2014. PMID: 24293456 Free PMC article. Review.

3

Predicting multiple sclerosis severity with multimodal deep neural networks.

Zhang K, Lincoln JA, Jiang X, Bernstam EV, Shams S. Zhang K, et al. BMC Med Inform Decis Mak. 2023 Nov 9;23(1):255. doi: 10.1186/s12911-023-02354-6. BMC Med Inform Decis Mak. 2023. PMID: 37946182 Free PMC article.

4

Assessing changes in relapse rates in multiple sclerosis.

Inusah S, Sormani MP, Cofield SS, Aban IB, Musani SK, Srinivasasainagendra V, Cutter GR. Inusah S, et al. Mult Scler. 2010 Dec;16(12):1414-21. doi: 10.1177/1352458510379246. Epub 2010 Sep 1. Mult Scler. 2010. PMID: 20810517 Review.

5

Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis.

Koch MW, Mostert J, Repovic P, Bowen JD, Wolinsky JS, Lublin FD, Strijbis E, Cutter G. Koch MW, et al. Eur J Neurol. 2022 Apr;29(4):1106-1116. doi: 10.1111/ene.15220. Epub 2021 Dec 26. Eur J Neurol. 2022. PMID: 34927308 Clinical Trial.

6

Recruitment of participants to a multiple sclerosis trial: the CombiRx experience.

Bhanushali MJ, Gustafson T, Powell S, Conwit RA, Wolinsky JS, Cutter GR, Lublin FD, Cofield SS. Bhanushali MJ, et al. Clin Trials. 2014 Apr;11(2):159-66. doi: 10.1177/1740774513517184. Clin Trials. 2014. PMID: 24686106 Free PMC article. Clinical Trial.

7

The impact of relapse definition and measures of durability on MS clinical trial outcomes.

Satyanarayan S, Cutter G, Krieger S, Cofield S, Wolinsky JS, Lublin F. Satyanarayan S, et al. Mult Scler. 2023 Apr;29(4-5):568-575. doi: 10.1177/13524585231157211. Mult Scler. 2023. PMID: 37119208 Free PMC article.

8

Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.

Koch MW, Mostert J, Zhang Y, Wolinsky JS, Lublin FD, Strijbis E, Cutter G. Koch MW, et al. Neurology. 2021 Sep 28;97(13):e1334-e1342. doi: 10.1212/WNL.0000000000012603. Epub 2021 Aug 10. Neurology. 2021. PMID: 34376508 Free PMC article.

9

Cerebellar pathology and disability worsening in relapsing-remitting multiple sclerosis: A retrospective analysis from the CombiRx trial.

Petracca M, Cutter G, Cocozza S, Freeman L, Kangarlu J, Margoni M, Moro M, Krieger S, El Mendili MM, Droby A, Wolinsky JS, Lublin F, Inglese M. Petracca M, et al. Eur J Neurol. 2022 Feb;29(2):515-521. doi: 10.1111/ene.15157. Epub 2021 Nov 17. Eur J Neurol. 2022. PMID: 34695274 Clinical Trial.

10

Variable results after rituximab in neuromyelitis optica.

Lindsey JW, Meulmester KM, Brod SA, Nelson F, Wolinsky JS. Lindsey JW, et al. J Neurol Sci. 2012 Jun 15;317(1-2):103-5. doi: 10.1016/j.jns.2012.02.017. Epub 2012 Mar 9. J Neurol Sci. 2012. PMID: 22405926 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year